vatelizumab
mAbexperimental
Vatelizumab is an immunomodulator. It binds to integrin alpha 2. — Wikipedia
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01659138)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Integrin alpha-2ANTAGONIST
ITGA2 antagonist
- Integrin alpha-2INHIBITOR
ITGA2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVatelizumab ↗
- ChEMBLCHEMBL1743086 ↗
Also known as
- sar339658
- vatelizumab
- vatelizumab
- vatelizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02306811 | Phase 2 | Feb 1, 2015 | Genzyme, Sanofi |
| NCT02222948 | Phase 2 | Sep 1, 2014 | Genzyme, Sanofi |
| NCT01861249 | Phase 2 | Jul 1, 2013 | Sanofi |
| NCT01659138 | Phase 2 | Aug 1, 2012 | Sanofi |
Showing 4 of 4 trials
Page 1 / 1